Tech

High Growth Tech Stocks to Watch in Asia June 2026

As global markets navigate a complex landscape marked by technology sector volatility and economic resilience, Asia’s tech industry continues to capture investor attention with its potential for high growth amidst uneven economic recoveries. In this environment, identifying strong stocks often involves looking for companies that demonstrate robust innovation capabilities and adaptability to shifting market dynamics, particularly in sectors like artificial intelligence where commercialization efforts are gaining momentum.

Top 10 High Growth Tech Companies In Asia

Name

Revenue Growth

Earnings Growth

Growth Rating

Shengyi Electronics

27.53%

32.56%

★★★★★★

Gold Circuit Electronics

36.81%

38.20%

★★★★★★

Fositek

29.08%

37.44%

★★★★★★

Zhongji Innolight

43.50%

46.32%

★★★★★★

Eoptolink Technology

40.03%

41.52%

★★★★★★

Suzhou TFC Optical Communication

39.49%

38.23%

★★★★★★

Mobvista

22.88%

41.07%

★★★★★★

eWeLLLtd

21.01%

20.06%

★★★★★★

Unimicron Technology

29.46%

54.03%

★★★★★★

CARsgen Therapeutics Holdings

63.86%

82.10%

★★★★★★

Click here to see the full list of 131 stocks from our Asian High Growth Tech and AI Stocks screener.

Here’s a peek at a few of the choices from the screener.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Aimed Bio Inc. focuses on developing therapeutic solutions for brain diseases, including neuro-oncological and degenerative conditions, with a market cap of ₩1.76 billion.

Operations: Aimed Bio Inc. engages in the development of therapeutic solutions targeting brain diseases, specifically neuro-oncological and degenerative conditions.

Aimed Bio, a rising star in Asia’s biotech sector, has demonstrated robust financial growth with an annual revenue increase of 29.7% and an impressive earnings surge of 76.5% per year. This performance outpaces the broader South Korean market’s growth rates of 16.3% for revenue and 32.9% for earnings, highlighting its competitive edge in a rapidly evolving industry. Despite a significant one-off loss of ₩1.3 billion affecting its recent financial outcomes, the company has transitioned to profitability this year, showcasing its resilience and potential for sustained growth. With positive free cash flow and expectations for continued aggressive earnings expansion over the next three years, Aimed Bio is well-positioned to capitalize on technological advancements and increasing health sector demands in Asia.

KOSDAQ:A0009K0 Revenue and Expenses Breakdown as at Jun 2026

Simply Wall St Growth Rating: ★★★★★☆

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button